¹⁸F-fluorodeoxyglucose (FDG) PET or ¹⁸F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study.

ABSTRACT:

Purpose

This study evaluated the ability of ¹⁸F-Fluorodeoxyglucose (FDG) and ¹⁸F-Fluorothymidine (FLT) imaging with positron emission tomography (PET) to measure early response to endocrine therapy from baseline to just prior to surgical resection in estrogen receptor positive (ER+) breast tumors.

Methods

In two separate studies, women with early stage ER+ breast cancer underwent either paired FDG-PET (n = 22) or FLT-PET (n = 27) scans prior to endocrine therapy and again in the pre-operative setting. Tissue samples for Ki-67 were taken for all patients both prior to treatment and at the time of surgery.

Results

FDG maximum standardized uptake value (SUVmax) declined in 19 of 22 lesions (mean 17% (range -45 to 28%)). FLT SUVmax declined in 24 of

SUBMITTER: Romine PE 

PROVIDER: S-EPMC8381552 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature